Black Hawk Acquisition Corporation Form 8-K Summary
Business Context and Reporting Period
Filed September 24, 2026, reporting events dated September 22, 2026. Black Hawk Acquisition Corporation entered into financing and related agreements with Vesicor Therapeutics, Inc. and Meteora Select Trading Opportunities Master, LP in connection with the proposed business combination with Vesicor.
Under the transaction, Black Hawk intends to domesticate as a Delaware corporation and change its name to Vesicor Therapeutics Holdings, Inc., with Vesicor becoming a wholly owned subsidiary.
Key Financial and Capitalization Terms
- Forward purchase transaction: Covers up to 1,350,000 shares, subject to potential upward adjustment for certain dilutive offerings. The initial price is based on the per-share redemption price in the business combination; the initial reset price is $10.00 per share.
- Trust account funding: At closing, the Company may pay Meteora from the trust account an amount based on the applicable number of shares and the initial price, reduced by amounts funded for Additional Shares.
- Non-redemption support: Meteora agreed on a commercially reasonable best-efforts basis to hold or reverse redemptions for up to 2,124,077 ordinary shares. The maximum does not require Meteora to acquire or retain any minimum number of shares. The payment per share will equal the final redemption price less $0.75.
- Subscription agreement: Meteora may purchase Additional Shares from the Company up to the Forward Purchase Agreement maximum, less Recycled Shares, at the initial price. Purchases are subject to a 9.9% beneficial ownership limitation unless waived.
- Standby equity purchase agreement: Following effectiveness of the required registration statement, PubCo may sell Meteora up to $200.0 million of common stock over generally 36 months, extendable by up to 24 months. There is no mandatory minimum utilization or non-usage fee.
- SEPA pricing: Ordinary advances will generally be priced at 97% of the applicable market price, subject to contractual limitations. Individual advances generally may not exceed 30% of the average daily traded amount over the preceding 10 trading days.
- Convertible pre-paid advances: If mutually agreed, advances may be documented by 12-month convertible notes funded at 85% of face value, reflecting a 15% original issue discount. The notes generally bear no interest absent default, with interest increasing to 18% during an uncured default.
- Commitment fee: PubCo will pay a fee equal to 0.50% of the $200.0 million SEPA commitment, or approximately $1.0 million, in cash or shares as permitted by the agreement.
- Expenses: Documented transaction expenses under the related agreements are capped at an aggregate of $75,000.
- Registration: PubCo must file a resale registration statement for SEPA securities no later than 60 days after closing and generally seek effectiveness within 60 days after filing. The initial registration statement must cover at least the greater of 10,000,000 shares or 300% of the shares issuable upon conversion of outstanding notes, subject to applicable limitations.
Material Changes Versus the Prior Comparable Period
This filing announces new financing, non-redemption, equity purchase and registration arrangements in connection with the proposed business combination. The filing does not provide comparative revenue, earnings, cash flow, margin, debt or liquidity figures, and therefore does not establish period-over-period operating changes.
Outlook, Risks and Unusual Items
- The proposed financing is contingent on the closing of the business combination and satisfaction of applicable contractual conditions.
- The Forward Purchase Agreement has a valuation date generally 36 months after closing and may be accelerated under specified delisting or registration-failure events.
- Meteora may terminate all or part of the forward transaction before the valuation date, subject to payment terms specified in the agreement.
- SEPA availability is subject to registration effectiveness, beneficial ownership limits initially set at 4.9% and potentially increasing to 9.9%, Nasdaq issuance limitations and other conditions.
- Issuances under the Subscription Agreement, SEPA, convertible notes and commitment-fee provisions may dilute existing shareholders. The securities are expected to be issued in reliance on private-placement exemptions and have not been registered under the Securities Act.
- Convertible note pricing may be based on a discount to future VWAP, subject to a floor and other adjustments, which may create additional dilution and market-price pressure.
- Registration failures may trigger specified remedies, including partial liquidated damages based on outstanding note principal.
- The filing provides no operating guidance, revenue outlook, profitability forecast or cash-flow forecast.
Investor Verification Checklist
- Verify whether and when the Vesicor business combination closes, including the proposed domestication and corporate name change.
- Confirm the final redemption price, actual number of Backstop Investor Shares and amount paid from the trust account.
- Determine the number of Recycled Shares and Additional Shares ultimately issued or purchased.
- Review the full Forward Purchase Agreement for reset, termination, valuation-date and dilution provisions.
- Monitor actual SEPA utilization, share issuances, convertible notes, conversion prices and resulting dilution.
- Confirm timely filing and effectiveness of the required resale registration statements.
- Review the Nasdaq share-issuance limitations and any required stockholder approval.
- Assess the company’s post-transaction cash needs and liquidity; the filing text does not provide a clear pro forma cash balance or operating cash-flow outlook.